Affiliation:
1. ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, Odisha, India
2. KIIT School of Biotechnology, Kalinga Institute of Industrial Technology Deemed to be University, Bhubaneswar, Odisha, India
Abstract
Background:
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), with a high global prevalence and mortality rate. To control the gruesome pathogen, a deep understanding of pathophysiology and host–pathogen interaction is essential for early diagnosis and novel drug development. Cytokines play a crucial role in infection and susceptibility, and their expressions could serve as potential biomarkers to enhance our understanding of Mtb pathophysiology for improved therapeutic approaches. This cross-sectional study investigates the levels of four important T-cell immune-mediated cytokines: interleukins (IL-6 and IL-10), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha in 80 cohort samples, with 20 people in each group.
Methods:
Following proper ethics and patient consent, we collected blood samples and isolated serum from all four groups: TB, type 2 diabetes mellitus (T2DM), type 2 diabetes–TB comorbidity (T2DM + TB), and a healthy individual as a control group (C). Furthermore, cytokine expression was measured in individual serum samples through the enzyme-linked immunosorbent assay method using commercial kits (Diaclone, French). Statistical significance was observed by analyzing triplicate data using t-tests and the one-way ANOVA method with GraphPad Prism 10.
Results:
The results showed that all four cytokine levels were higher (P ≤ 0.0001) than the control, especially IL-6, IL-10, and IFN-γ, which were found to be upregulated in T2DM + TB samples (P ≤ 0.0001) than individual TB or T2DM samples.
Conclusion:
The high levels of cytokines in comorbidity cases raise the risk of insulin resistance and the severity of TB infection. These levels of expression could be used to keep track of the Mtb infection status or severity, aid in early diagnosis as a possible biomarker, and suggest possible treatment plans.
Reference30 articles.
1. Editorial: Drug-ability strategies for potential antimycobacterial candidate: Opportunities and challenges;Swain;Front Pharmacol,2023
2. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects;Visca;Pulmonology,2021
3. Acute kidney injury in human immunodeficiency virus, tuberculosis, and human immunodeficiency virus/tuberculosis patients on treatment and its association with host predicting factors, in South-West region of Cameroon a cohort study;Enoh;J Prev Diagn Treat Strategies Med,2023
4. Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis;Swain;Emerg Microbes Infect,2020
5. Tuberculosis control: Getting back on track in the era of COVID-19;Burki;Lancet Respir Med,2022